XML 55 R36.htm IDEA: XBRL DOCUMENT v3.7.0.1
Business, Basis of Presentation and Business Combinations (Details Textual)
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Apr. 28, 2016
USD ($)
$ / shares
shares
Oct. 31, 2015
USD ($)
Oct. 05, 2015
USD ($)
Sep. 30, 2015
USD ($)
May 31, 2015
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Apr. 28, 2016
CAD
CAD / shares
May 20, 2015
USD ($)
Business Acquisition [Line Items]                          
Stockholders' Equity, Reverse Stock Split               On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares outstanding. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares outstanding (herein referred to collectively as the Reverse Stock Splits). All share and per share amounts in this report have been adjusted to reflect the effect of these Reverse Stock Splits.   On June 8, 2015, we reincorporated as a domestic Delaware corporation under Delaware General Corporate Law and changed our name from Rosewind Corporation to Aytu BioScience, Inc., and effected a reverse stock split in which each common stockholder received one share of common stock for every 12.174 shares outstanding. On June 30, 2016, Aytu effected another reverse stock split in which each common stockholder received one share of common stock for every 12 shares outstanding (herein referred to collectively as the “Reverse Stock Splits”).      
Payments to Acquire Businesses, Gross                   $ 0 $ 1,000,000    
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset                   0 664,000    
Amortization of Intangible Assets     $ 174,000             664,707 90,662    
Business Combination, Contingent Consideration, Liability, Total                   701,000      
Accretion Expense                     $ 6,000,000    
Developed Technology Rights [Member]                          
Business Acquisition [Line Items]                          
Amortization of Intangible Assets               $ 520,000   520,000      
Trade Names [Member]                          
Business Acquisition [Line Items]                          
Amortization of Intangible Assets               810,000   140,000      
Customer Contracts [Member]                          
Business Acquisition [Line Items]                          
Amortization of Intangible Assets               140,000   810,000      
Prostascint Business [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total         $ 2,400,000               $ 2,391,000
Payments to Acquire Businesses, Gross         1,000,000                
Business Combination, Consideration Transferred, Liabilities Incurred       $ 227,000 227,000                
Business Combination, Contingent Consideration Arrangements, Change in Range of Outcomes, Contingent Consideration, Liability, Value, High         $ 2,500,000                
Business Combination Contingent Consideration Percentage         8.00%                
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset         $ 664,000     730,000   699,000      
Amortization of Intangible Assets           $ 40,000 $ 40,000 80,000 $ 80,000        
Business Combination Consideration Transferred Product Inventory         500,000                
Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Developed Technology Rights [Member]                          
Business Acquisition [Line Items]                          
Finite-Lived Intangible Assets, Gross           790,000   790,000   790,000      
Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Trade Names [Member]                          
Business Acquisition [Line Items]                          
Finite-Lived Intangible Assets, Gross           80,000   80,000   80,000      
Jazz Pharmaceuticals Inc [Member] | Prosta Scint [Member] | Customer Contracts [Member]                          
Business Acquisition [Line Items]                          
Finite-Lived Intangible Assets, Gross           720,000   720,000   720,000      
Primsol Business [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total     $ 1,799,000                    
Payments to Acquire Businesses, Gross   $ 500,000     500,000                
Business Combination, Consideration Transferred, Liabilities Incurred   142,000     142,000         1,892,000      
Amortization of Intangible Assets           61,000 $ 51,000 122,000 $ 51,000        
Business Combination Consideration Transferred Inventory   102,000     102,000     102,000   102,000      
Business Combination Consideration Transferred Product Inventory   40,000     40,000                
Business Combination Consideration Transferred Work In Process Inventory               80,000   80,000      
Primsol Business [Member] | Paid on April 1, 2016 [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Consideration Transferred, Liabilities Incurred   500,000     500,000                
Primsol Business [Member] | No Later Than July 01, 2016 [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Consideration Transferred, Liabilities Incurred   500,000     500,000                
Primsol Business [Member] | No Later Than November 30, 2016 [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Consideration Transferred, Liabilities Incurred   $ 250,000     $ 250,000                
Natesto [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets, Total           10,500,000   10,500,000   10,500,000      
Payments to Acquire Businesses, Gross $ 2,000,000                 5,400,000      
Business Combination, Consideration Transferred, Liabilities Incurred                   3,200,000      
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset               3,300,000   $ 3,200,000      
Finite-Lived Intangible Assets, Remaining Amortization Period                   8 years      
Amortization of Intangible Assets           330,000   659,000          
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | shares 12,245,411                        
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned $ 2,000,000                     CAD 2,534,800  
Business Acquisition, Share Price | (per share) $ 0.16                     CAD 0.207  
One Time Non-Refundable Payments $ 37,500,000                        
Other Accrued Liabilities           620,000   620,000          
Accretion Expense           58,000   104,000          
Natesto [Member] | License And Supply Agreement [Member]                          
Business Acquisition [Line Items]                          
Other Accrued Liabilities           $ 4,000,000   $ 4,000,000          
Natesto [Member] | First Milestone [Member] | License And Supply Agreement [Member]                          
Business Acquisition [Line Items]                          
One Time Non-Refundable Payments 2,500,000                        
Sales Revenue Target 25,000,000                        
Natesto [Member] | Second Milestone [Member] | License And Supply Agreement [Member]                          
Business Acquisition [Line Items]                          
One Time Non-Refundable Payments 5,000,000                        
Sales Revenue Target 50,000,000                        
Natesto [Member] | Third Milestone [Member] | License And Supply Agreement [Member]                          
Business Acquisition [Line Items]                          
One Time Non-Refundable Payments 7,500,000                        
Sales Revenue Target 75,000,000                        
Natesto [Member] | Forth Milestone [Member] | License And Supply Agreement [Member]                          
Business Acquisition [Line Items]                          
One Time Non-Refundable Payments 10,000,000                        
Sales Revenue Target 100,000,000                        
Natesto [Member] | Fifth Milestone [Member] | License And Supply Agreement [Member]                          
Business Acquisition [Line Items]                          
One Time Non-Refundable Payments 12,500,000                        
Sales Revenue Target 125,000,000                        
Natesto [Member] | Second Upfront [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Consideration Transferred, Liabilities Incurred 2,000,000                        
Natesto [Member] | Third Upfront [Member]                          
Business Acquisition [Line Items]                          
Business Combination, Consideration Transferred, Liabilities Incurred $ 4,000,000